News
08-10-2010
EryDel at BIOTECHNICA 2010 in Hannover
Hannover, 5-7 october 2010 - More than 9,500 visitors from 40 different nations attended BIOTECHNICA to find out about the latest biotechnology trends in the fields of healthcare, food production, industry, environmental protection, lab equipment and bioinformatics - as well as to transact new business deals.
In this context, Erydel presented its products to visitors in a dedicated area inside the stand of Marche Biotech.
About BIOTECHNICA 2010
End-of-show report for BIOTECHNICA 2010: European networking hub for industry and science
- Stronger rate of participation from abroad, higher ratio of trade visitors
- Conference program's innovative content creates strong impression
Drawing to a successful close, BIOTECHNICA 2010 has generated a positive mood in the international life science industry: "BIOTECHNICA has demonstrated the importance of biotechnology to all areas of life as well as the economy," commented Stephan Ph. Kühne, Member of the Managing Board of Deutsche Messe AG, Hannover, at the end of Europe's biggest biotechnology and life science exhibition. "It has once again underscored its status as a networking hub for industry and science," he added. "Many exhibitors are leaving Hannover with a sense of optimism and fresh ideas for brisk post-show business. Now the task at hand is to also convince the broad public of the great potential offered by biotechnology."
For more information, log on to www.biotechnica.de
» Download PDF
13-09-2010
EryDel has CE Marked its New Medical Devices for automatic encapsulation of
Drugs into Human Autologous Red Blood Cells
EryDel SpA has reached the certification of its Quality System according to two standards: EN ISO 13485:2003 / AC-2007 and ISO 9001:2008.
EryDel also became qualified medical devices manufacturer by CE marking their new products. The certifications were issued by the TÜV SÜD Group (EC 0123) notified body under the European Medical Devices Directive 93/42 and subsequent updates.Purpose of the EC certificate issued by TÜV SÜD Product Service GmbH to EryDel Spa: Design and development, production and distribution of disposable and electro-medicals devices for blood processing.
Current medical devices CE marked by EryDel:
-Disposable (single use) Medical device (ERY-Kit family) dedicated to blood processing that may subsequently be reinfused to the same donor. More specifically, this is a disposable medical device that allows the encapsulation of Dexamethasone Sodium Phosphate inside red blood cells, that are used as biocompatible carriers and innovative route of administration. The device is non-toxic, non-pyrogenic, supplied sterile in individual package and sterilized with ethylene oxide.
- Electro-medical equipment (RED CELL LOADER family). Used in combination with the disposable family ERY-KIT, it is the non-invasive device, fully automatic and highly reproducible, that allows the loading of drugs and other biological agents within red blood cells.
» Download PDF
14-01-2010
Erydel will be present at Biosquare Forum Congress in Geneva.
From 1 to 2 February 2010, innovators, entrepreneurs, finance and industry representatives of the life sciences sector will meet in Geneva (Switzerland), at the Crowne Plaza Hotel, on the occasion of the 8th edition of Biosquare. This edition aims to face the paradigm shift that the life sciences sector is currently experiencing. Indeed, both pharmaceutical and biotechnology companies are investigating highly innovative technologies which lie outside their traditional fields of expertise. The tools and technologies which stem from in vitro diagnostics, medical devices, nanotechnologies and in silico are all converging towards biopharmaceutical research to accelerate the development of innovative molecules that are delivered in a targeted manner to patients. This strategy of alliances and interdisciplinarity illustrates the concept of bioconvergence, the central theme of BioSquare 2010.
In the second day of the event, EryDel will be introduced by the Company Manager, Mr Giovanni Mambrini, who will speak for about 15 minutes.
The conference will allow the participants to meet with all life sciences decision makers from emerging and leading pharmaceutical, biotech, medtech, nanotech, diagnostic and in silico companies for broader opportunities.
BioSquare represents a real opportunity for companies of all sizes, from pharmaceutical giants to mature companies and innovative start-ups, to meet potential partners through targeted presentations, the organisation of B-to-B meetings and the new "Corridor of Innovation".
For more information, log on to www.biosquare.com
23-09-2009
EryDel posted an IBox-out at Innoget.com
Link: http://www.innoget.com/iboxout/Erydel-46.html
16-09-2009
EryDel has been added to the Tornado Insider Radar Database, The source for Europe's high-growth high-tech community!
Link: http://www.tornado-insider.com/radar/compShow.asp?compID=13097
15-06-2009
EryDel at Healthcare Innovation Tournment in Barcelona
EryDel, finalist of the Healthcare Innovation Tournament at HiT Barcelona’09
Barcelona, 4 June, 2009 - HiT Barcelona - World Innovation Summit, announced the 15 finalists of its Healthcare Innovation Marketplace Tournament. All participating companies are in an advanced stage of development of products or services in healthcare delivery, medical technology, therapeutics and diagnostics and seek support from partners with the objective of achieving market penetration.
EryDel is one of 15 finalists who have been classified in two categories (therapeutic and diagnostic / medical technology and others) and will be reviewed by a jury panel of experts in the field, Directors of companies involved in Biotechnology and Life Sciences and Venture Capital firms.
The 2-day Healthcare Innovation Marketplace programme combines keynote addresses and panel discussions by prominent experts in the biomedical and life science fields, along with investors and entrepreneurs:
Keynote speakers
- Chris Lowe, Director, Institute Biotechnology; Professor of Biotechnology, University of Cambridge
- Irene Norstedt, Head of Health Research Directorate, European Commission,
- Joseph Feczko, Former Senior Vice President and Chief Medical Officer, Pfizer Inc,
The objective of the Healthcare Innovation Marketplace is to foster entrepreneurs and investor partnerships to drive strategically innovative projects in the critical fields of life science and technologies and to become the global reference platform to share knowledge and actively network.
About HiT Barcelona
HiT Barcelona is a unique global event bringing together leading innovators, experts, entrepreneurs and investors to share and expand knowledge and to promote strategic business projects via tournaments. Focused on three key sectors with a high growth potential, Telecom, CleanTech and Healthcare, HiT Barcelona combines top-level plenary sessions (Plenary Congress) with a programme of meetings and sector-specific competitions of some of the most innovative business projects worldwide (Innovation Marketplaces). The event will also host the first ever truly international “Business-Plan/Early-Stage” competition for entrepreneurs, the Global Entrepreneurship Competition.
HiT Barcelona is an initiative of the Spanish Ministry of Industry, Commerce and Tourism, the Autonomous Government of Catalonia, the Barcelona City Council (via their Finance, Economy and Innovation Departments), the Barcelona Chamber of Commerce and La Caixa. It is organised by the Fira de Barcelona and the Barcelona Plà Estrategic. The first edition of the event is expected to bring to Barcelona over 2,500 delegates from the 17th to the 19th of June 2009.
For more press information about HiT Barcelona:
Ricardo Caballero / Marta Melgosa / Folc Lecha
Tel: +34 93 318 4669 / +34 93 233 3555
Email: rc@homeatc.com / mmn@homeatc.com / flecha@firabcn.es
16-04-2009
EryDel awarded at Healthcare Biotech Forum
EryDel S.p.A. awarded at Healthcare Biotech Forum
On 30 and 31 March 2009 EryDel SpA, a spin-off of the University of Urbino, took part in Biotech Healthcare Forum, an initiative promoted by the Agency for the Promotion of European Research (APRE), which was held in Rome, winning the Best Presentation Award. It was given by a panel of international reviewers and it is expression of the great interest that the project has generated.
EryDel S.p.A. was founded in March 2007 by the initiative of Prof. Mauro Magnani and Prof. Luigia Rossi of the Urbino University "Carlo Bo". The company operates in the field of Biotech Pharmaceuticals using autologous red blood cells (from the same patient) to deliver and administer innovative therapies. The technology is covered by worldwide patents and has already a large number of potential applications in the pipeline.
Healthcare Biotech Forum (http://www.e-unlimited.com/events/p200292/overview.asp) as well as being a showcase for innovation in the field of Health Biotechnology, is an important opportunity to make known innovative companies and researchers to an audience of experts from across Europe, big pharma companies and venture capitalists.
The company General Manager, Dr. Giovanni Mambrini, welcomes the award and expresses great satisfaction for the first results achieved by the company which is currently engaged in the realization of an European Multicentre Phase III Clinical Study on Inflammatory Bowel Diseases (Crohn Disease). The objectives of the study concern the possibility of encapsulating an anti-inflammatory drug (a corticosteroid analogue) in red blood cells and thereby obtaining a low and constant release into the circulation (up to 30 days). In this way a nearly complete reduction of serious side effects of these drugs, which are mainly shown following their chronic intake, is obtained.
Thursday 16th of April 2009
16-12-2008
Phase III Clinical Trial approval
The Ethical Committee of Principal Investigator (Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy) approved the Phase III Study Protocol titled: "Multicenter, randomized, double-blind, parallel-group study of intra-erythrocyte dexamethasone versus placebo in patients with steroid-dependent Crohn’s disease".
15-08-2008
Red cells for fluorangiography
Click to view the abstract:
http://www.ncbi.nlm.nih.gov/pubmed/18708621?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.
Pubmed_ResultsPanel.Pubmed_RVDocSum
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5510-6. Epub 2008 Aug 15. Links
Observation of erythrocyte dynamics in the retinal capillaries and choriocapillaris using ICG-loaded erythrocyte ghost cells.Flower R, Peiretti E, Magnani M, Rossi L, Serafini S, Gryczynski Z, Gryczynski I.
Department of Ophthalmology, New York University School of Medicine, New York, USA. rflower@comcast.net
PURPOSE: To find evidence of retinal vasomotion and to examine the relationship between erythrocyte dynamics and previously observed high-frequency pulsatile blood flow through the choriocapillaris.
METHODS: An osmotic shock technique was used to encapsulate indocyanine green (ICG) dye in erythrocyte ghost cells at a concentration that produced maximum cell fluorescence. By obviating the plasma staining that results from aqueous ICG's high affinity for plasma proteins, high contrast was maintained between reinjected ICG-loaded erythrocytes and their plasma background. High-speed, high-magnification ICG angiograms showing individual cell movement were recorded from the intact eyes of four monkeys and three rabbits for periods up to 30 seconds. RESULTS: In monkey retinal perifoveal capillaries, numerous erythrocytes were seen to pause for as long as 20 seconds and then resume transit. Similar pausing behavior was observed in the subfoveal choriocapillaris. Individual erythrocytes also were seen to pause in the rabbits' choriocapillaries below the medullary rays, where visualization of the cells was uninhibited by overlying retinal vasculature or dense pigment. CONCLUSIONS: Reinjected ICG-loaded erythrocytes permit routine visualization of retinal capillary and choriocapillaris hemodynamics of the intact eye. It is speculated that erythrocyte-pausing in both microcirculations facilitates metabolic exchange across capillary walls. In retinal capillaries, pausing is presumed to result from vasomotion-which has been postulated as necessary for the inhibition of retinal edema-and in choriocapillaries, to result from the shifting distributions of local perfusion pressures within the network of capillary vessel segments that comprise each lobular area of the choriocapillaris vascular plexus. |
